Conditions: Atopic Dermatitis
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 16
Healthy volunteers: no

Brief summary:
The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.

Detailed description:
To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis.

Arms:
arm 1: Patients dosed with 20 mg orally of Apremilast BID for 3 months. arm 2: Patients dosed with 30 mg orally of Apremilast BID for 6 months.

Interventions: intervention 1: Apremilast
Intervention descriptions: intervention 1: 20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.

Protocol document: